06th week of 2010 patent applcation highlights part 34 |
Patent application number | Title | Published |
20100034709 | FLUID BED REACTORS AND ASSOCIATED METHODS - In one embodiment of the present invention a fluid bed reactor is provided, comprising: | 2010-02-11 |
20100034710 | Residual Oil Coking Scheme - A coking process and apparatus may include cracking a hydrocarbon feed stream with a catalyst, generating a hot flue gas from regenerating said catalyst, directing the hot flue gas into a spray contactor, spraying a heavy residual oil into the spray contactor, and coking the heavy residual oil utilizing the hot flue gas as a heat source. The hydrocarbon feed stream and the heavy residual oil may each or both be generated by a solvent deasphalter. The coking process produces a solid coke product and volatile hydrocarbons which leave with the hot gas and may be burned in an oxidizer to generate steam with the pressure energy recovered by a turbo-expander. | 2010-02-11 |
20100034711 | CATALYTIC CRACKING RISER REACTOR - Catalytic cracking riser reactor extending between an inlet for hydrocarbonaceous feed and catalyst particles and an outlet for discharging cracked products and spent catalyst particles, which riser reactor has been provided with at least one contacting device, wherein the contacting device comprises a composite of refractory material and a metal structure, which metal structure is connected to the outer wall of the riser reactor. If more contacting devices have been provided, they are preferably axially spaced apart and are disposed along the inner surface of the riser reactor. | 2010-02-11 |
20100034712 | EXHAUST-GAS CONVERTING APPARATUS - A storage catalyst | 2010-02-11 |
20100034713 | PROCESS FOR SEPARATING A CHEMICAL ELEMENT FROM URANIUM (VI) STARTING FROM A NITRIC AQUEOUS PHASE, IN AN EXTRACTION CYCLE FOR THE URANIUM - A chemical element to be very efficiently separated from uranium starting from an acid aqueous phase, in an extraction cycle for the uranium, when this chemical element is present in said phase at a concentration less than that of the uranium, or even as a trace element, and when it is moreover less extractable by the extractant used in this extraction cycle than is the uranium. The chemical element can notably be neptunium(IV) or thorium 228. | 2010-02-11 |
20100034714 | PROCESSES FOR PRODUCING TITANIUM DIOXIDE - Provided are processes for the production of titanium dioxide from ilmenite. In these processes, ilmenite is digested with aqueous trimethylammonium hydrogen oxalate. Iron from the ilmenite precipitates as a hydrated iron oxalate and is removed by filtering, leaving a titanium-rich solution. The titanium-rich solution can be further processed to form titanium dioxide. | 2010-02-11 |
20100034715 | RECOVERY OF LEAD IN FORM OF HIGH PURITY LEAD CARBONATES FROM SPENT LEAD BATTERIES INCL. ELECTRODE PASTE - Wet process of low environmental impact recovers the lead content of an electrode slime and/or of lead minerals in the valuable form of high purity-lead carbonates that are convertible to highly pure lead oxide by heat treatment in oven at relatively low temperature, perfectly suited for making active electrode pastes of new batteries or other uses. The process basically comprises the following steps: a) adding sulphuric acid to a different acid leach suspension of the starting impure material for converting all dissolved lead compounds to insoluble lead sulphate; b) separating the solid phase constituted by lead sulphate and undissolved impurities from the acid leach solution; c) selectively dissolving lead sulphate contained in said separated solid phase in an aqueous solution of a lead solubilizing compound comprising preferably sodium acetate; d) separating the solution containing dissolved lead sulphate from the solid phase residue including undissolved impurities; e) adding to the separated solution of lead sulphate a carbonate of the same cation of said dissolving compound for forming insoluble lead carbonate and/or and lead oxycarbonate and a dissolved sulphate of the same cation; f) separating the precipitated carbonate and/or oxycarbonate of lead from the dissolving solution now containing also sulphate of the cation of said solubilizing compound. | 2010-02-11 |
20100034716 | Separation method for zinc sulfide - The separation method for zinc sulfide, in the hydrometallurgical process by a High Pressure Acid Leach for nickel oxide ore comprising leaching and solid/liquid separation step, neutralization step, zinc removal step, and nickel recovery step, which can inhibit clogging of a filter cloth and reduce a frequency of washing operation and replacement operation of a filter cloth by improving filtration performance of zinc sulfide, and inhibit decrease of nickel recovery ratio, in the zinc removal step in which zinc sulfide is formed by adding a sulfurizing agent to the neutralization final liquid containing zinc as well as nickel and cobalt and zinc sulfide is separated to obtain a mother liquid for nickel recovery containing nickel and cobalt. | 2010-02-11 |
20100034717 | VANADIUM-FREE CATALYST FOR SELECTIVE CATALYTIC REDUCTION AND PROCESS FOR IT'S PREPARATION - Selective catalytic reduction with ammonia or a compound that decomposes to ammonia is a known method for the removal of nitrogen oxides from the exhaust gas of primarily lean-burn internal combustion engines. The vanadium-containing SCR catalysts that have long been generally used for this are characterized by a good conversion profile. However, the volatility of vanadium oxide can, at higher exhaust gas temperatures, lead to the emission of toxic vanadium compounds. Zeolite-based SCR catalysts, which are used in particular in discontinuous SCR systems, constitute a very cost-intensive solution for the problem. | 2010-02-11 |
20100034718 | Moving Bed Catalyst Regeneration Apparatus with Integral CO Oxidation Zone and Method of Use to Accelerate Coke Burning - A combination of moving bed regeneration technology and CO oxidation technology is used in a novel moving bed regeneration apparatus containing an integral CO oxidation zone to solve the problem of regenerating a coke-containing catalyst that does not contain a CO oxidation promoter without generating an effluent flue gas stream containing hazardous and undesired amounts of CO. The CO oxidation zone is located in the flue gas collection zone within the moving bed regeneration apparatus and functions autogenously to eliminate the CO hazard by oxidizing CO to CO | 2010-02-11 |
20100034719 | NOVEL LANTHANIDE BETA-DIKETONATE PRECURSORS FOR LANTHANIDE THIN FILM DEPOSITION - Methods and compositions for depositing a film on one or more substrates include providing a reactor and at least one substrate disposed in the reactor. At least one lanthanide precursor is provided in vapor form and a lanthanide thin film layer is deposited onto the substrate. | 2010-02-11 |
20100034720 | METHOD OF PREPARATION OF TALCUM PRODUCT WITH HIGH PURITY DEGREE - The method which is the subject of protection is characteristic by the fact that firstly is made the suspension consisting of 10 to 20 mass % of mineral talc and 80 to 90 mass % of water; resulting suspension is homogenized and thereafter is heated to the temperature 50° to 70° C. To heated suspension is then added 37% hydrochloric acid in the amount of 1 to 6 mass % under continuous stirring. After reaching pH 3 to 5 and increasing the temperature up to 85° C., to the suspension is then added concentrated sulphuric acid in the amount of 1 to 5 mass %. The suspension is further maintained at the temperature up to 90° C., then it is chilled to the ambient temperature and thereafter is separated the sediment which is finally dried at the temperature 140° to 160° C. after washing with water and reaching pH 5 to 6. | 2010-02-11 |
20100034721 | Method and apparatus for manufacturing trichlorosilane - An apparatus | 2010-02-11 |
20100034722 | Apparatus for producing trichlorosilane and method for producing trichlorosilane - An apparatus for producing trichlorosilane includes: a decomposing furnace, a heating unit heating the inside of the decomposing furnace, a raw material supplying tube for guiding polymer and hydrogen chloride to be guided to the inner bottom portion of the decomposing furnace, and a gas discharge tube for discharging reaction gas from the top of the reaction chamber provided between the outer peripheral surface of the raw material supplying tube and the inner peripheral surface of the decomposing furnace, a fin, which guides a fluid mixture of the polymer and the hydrogen chloride supplied from the lower end opening of the raw material supplying tube to be agitated and rise upward in the reaction chamber, and is formed integrally with at least one of the outer peripheral surface of the raw material supplying tube and the inner peripheral surface of the decomposing furnace. | 2010-02-11 |
20100034723 | METHOD AND APPARATUS FOR REFINING A MOLTEN MATERIAL - A method for the directional solidification of silicon or other materials. A cooled plate is lowered into a silicon melt and an ingot of solid silicon is solidified downwards. | 2010-02-11 |
20100034724 | Carbon Dioxide Capture - A method of carbon dioxide capture is disclosed. In a step (a) anhydrous sodium carbonate is separated from a first aqueous solution formed by reacting carbon dioxide and an aqueous solution of sodium hydroxide. In step (b) the anhydrous sodium carbonate is treated by causticization to generate carbon dioxide and sodium hydroxide. The first aqueous solution of step (a) is formed by scrubbing a gas containing carbon dioxide with an aqueous solution of sodium hydroxide. | 2010-02-11 |
20100034725 | Preferential Growth of Single-Walled Carbon Nanotubes with Metallic Conductivity - The present disclosure is directed to a method of producing metallic single-wall carbon nanotubes by treatment of carbon nanotube producing catalysts to obtain the desired catalyst particle size to produce predominantly metallic single wall carbon nanotubes. The treatment of the carbon nanotube producing catalyst particles involves contacting the catalyst particles with a mixture of an inert gas, like He, a reductant, such as H | 2010-02-11 |
20100034726 | Process Producing Activated Carbon Having A High Catalytic Activity - Process for producing activated carbon having a high catalytic activity, in which a carbonaceous material is brought into contact with nitrogen compounds, wherein the carbonaceous material is partially gasified with a mixture of steam, nitrogen and CO | 2010-02-11 |
20100034727 | PROCESS FOR PRODUCING GYPSUM - The invention relates to a process for the preparation of a gypsum product wherein calcium sulphate hemihydrate and/or calcium sulphate anhydrite and water are contacted so that the calcium sulphate hemihydrate and/or calcium sulphate anhydrite and the water react with each other and form a gypsum product. The reaction mixture has a dry matter content of 34-84% by weight in order to obtain a gypsum product which consists of crystals that are small, flat and of as equal size as possible. The invention also relates to a product prepared by this process. A gypsum product is formed which consists of essentially intact crystals having a size of between 0.1 and below 2.0 μm. The products are applicable e.g. as fillers or coating pigments in e.g. paper industry. | 2010-02-11 |
20100034728 | Method for producing layer-structure nanoparticles - Provided is a method of producing layer-structure nanoparticles, which includes the steps of: producing a liquid mixture by adding a metal halide precursor and a sulfur precursor into an organic solvent containing amine; producing layer-structure metal sulfide nanoparticles by heating the liquid mixture at a predetermined temperature; and separating the metal sulfide nanoparticles from the liquid mixture. | 2010-02-11 |
20100034729 | Iron Composition Based Water Filtration System for the Removal of Chemical Species Containing Arsenic and other Metal Cations and Anions - An iron composition having a plurality of elemental components is disclosed. The major component is an iron component of at least about 68% to about 92% iron by weight. Other components by weight include manganese; cerium; carbon; phosphorous; sulfur; aluminum; silicon; chromium; copper; and zinc. Combined with layers of sand, brick chips and/or charcoal, the iron composition can be used to create a water filter for filtering inorganic arsenic species and soluble metal ions out of water. To enhance hydrous ferric oxide complexation and precipitation, the iron composition may be treated with food grade acids or a water mixture. | 2010-02-11 |
20100034730 | One-step, paste-state mechanochemical process for the synthesis of zinc oxide nanoparticles - The present subject matter provides a time- and energy-saving paste-state mechanochemical process to synthesize zinc oxide nanoparticles. Our nanoparticles are small, have abundant surface hydroxyl groups and exhibit excellent UV blocking characteristics. One embodiment involves a process for preparing zinc oxide nanoparticles comprising grinding, milling, or a combination thereof a mixture comprising (a) at least one zinc salt, (b) at least one additional inorganic salt, and (c) at least one alkali hydroxide compound. | 2010-02-11 |
20100034731 | Fuel Removal System for Hydrogen Implanted in a Nanostructure Material - According to one embodiment, a method for removing a gas from a nanostructure material includes a providing gas that is implanted in a carbon nanostructure material. The nanostructure material is subjected to a microwave field to remove the hydrogen from the nanostructure material. | 2010-02-11 |
20100034732 | Hydrogen production method - A method of producing hydrogen is provided that includes exposing a hydrogen-extracting (H-x) material to water, where the H-x material includes a crystal structure having interstitial space available for the insertion of protons and the water can be liquid water or vapor water. A spontaneous electrochemical reaction occurs, whereby water chemically decomposes in contact with the H-x material, the resulting hydrogen is stored in the H-x material and the resulting oxygen is emitted as a gas. This reaction proceeds until it is limited by a hydrogen loading capacity of the H-x material and/or the electrochemical potential of the H-x material relative to the water. The H-x material is heated to recover the stored hydrogen in a temperature range of 20 to 1000 degrees Celsius. This process is reversible, as it can be repeated many times. No electricity or consumable chemicals are required. | 2010-02-11 |
20100034733 | CATALYST FOR DECOMPOSITION OF FORMIC ACID, METHOD FOR DECOMPOSING FORMIC ACID, PROCESS FOR PRODUCING HYDROGEN, APPARATUS FOR PRODUCING AND DECOMPOSING FORMIC ACID, AND METHOD FOR STORING AND GENERATING HYDROGEN - The present invention provides a catalyst for the decomposition of formic acid including a dinuclear metal complex represented by a formula (1) below, a tautomer or stereoisomer thereof, or any of their salts, | 2010-02-11 |
20100034734 | SYSTEM AND METHOD FOR QUANTITATIVE MOLECULAR BREAST IMAGING - A system and method for performing quantitative lesion analysis in molecular breast imaging (MBI) using the opposing images of a slightly compressed breast that are obtained from the dual-head gamma camera. The method uses the shape of the pixel intensity profiles through each tumor to determine tumor diameter. Also, the method uses a thickness of the compressed breast and the attenuation of gamma rays in soft tissue to determine the depth of the tumor from the collimator face of the detector head. Further still, the method uses the measured tumor diameter and measurements of counts in the tumor and background breast region to determine relative radiotracer uptake or tumor-to-background ratio (T/B ratio). | 2010-02-11 |
20100034735 | TARGETED NANOPARTICLES FOR CANCER DIAGNOSIS AND TREATMENT - The invention provides modified gold nanoparticles that enable a non-invasive, real time, targeted cancer imaging-therapeutic in one step. After reaching the cancer targets, the designed targeted gold nanoparticles significantly enhance conventional treatment modalities at the cellular level. In this aspect the gold nanoparticles of the invention are modified to be bound to a Positron Emission Tomography (PET) tracer. | 2010-02-11 |
20100034736 | IDENTIFICATION OF CANCER STEM CELLS USING GENETIC MARKERS - The invention relates to the identification of markers for cancer stem cells. These markers can be used in a number of different ways, including diagnosis and therapy. In particular, the invention relates to a method of detecting, identifying and/or quantifying cancer stem cells, the method comprising the step of assessing the level of expression; the activity; or the sequence of the SLUG, OVOL1 and/or OVOL2 gene, promoter and/or expression product in a cell. | 2010-02-11 |
20100034737 | JUNCTIONAL ADHESION MOLECULE-C (JAM-C) BINDING COMPOUNDS AND METHODS OF THEIR USE - The present invention relates to the use of a compound that specifically binds to JAM-C or JAM-B for the treatment of gliomas. More specifically the invention relates to the use of an antagonist of JAM-B or JAM-C for the treatment of glioma, in particular astrocytoma. | 2010-02-11 |
20100034738 | Structural Variants of Antibodies for Improved Therapeutic Characteristics - The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 V | 2010-02-11 |
20100034739 | Fungus-Specific Imaging Agents - The disclosure relates to an imaging composition including a fungus-specific peptide and an imaging material. Another imaging composition includes a fungus-specific peptide and a chelator able to chelate a radionuclide. The disclosure also provides to a method of detecting a fungal infection. The method includes administering an imaging agent to a patient. The imaging agent comprises a fungus-specific peptide and an imaging material. Then one may detect the imaging agent in the patient. Detecting retained imaging agent in a tissue or organ indicates fungal infection of the tissue or organ. | 2010-02-11 |
20100034740 | RADIOFLUORINATION METHODS - The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes. | 2010-02-11 |
20100034741 | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor - The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the α7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express α7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity. | 2010-02-11 |
20100034742 | MODULAR MONOLAYER COATINGS FOR SELECTIVE ATTACHMENT OF NANOPARTICLES TO BIOMOLECULES - Nanoparticles are functionalized for use as bio-imaging probes using a novel, modular approach. Particle surface modification is based on a phosphonate monolayer platform on which was built a multi-segmented, multi-functional film: the first segment provided hydrolytic stability, the second aqueous suspendability, and the third, selectivity for cell attachment. In vitro imaging experiments visualized nanoparticle—cell surface binding. Peptide-derivatized nano-particles were not displaced from cells by soluble peptide. Methods for coating the host particles and use of rare earth ion-doped particles in imaging methods and photodynamic therapy methods are also disclosed. | 2010-02-11 |
20100034743 | Raman Characterization of Transplant Tissue - A system and method for determining a disease state and clinical outcome of a sample. A sample is illuminated to produce Raman scattered photons, the Raman scattered photons are assessed to generate a Raman spectroscopic data set representative of the sample, wherein said Raman spectroscopic data set comprises at least one of: a Raman spectra of the sample and a spatially accurate wavelength resolved Raman image of the sample; the Raman spectroscopic data set is evaluated using a chemometric technique to classify the disease state of the sample as: acute, chronic, incipient, or none. In one embodiment, the chemontric technique is principle component analysis. In another embodiment, the sample is obtained prior to transplantation and analysis can determine the likelihood of rejection by a host. | 2010-02-11 |
20100034744 | Method For Screening Anti-HIV Drugs and A Diagnostic Method of AIDS - The present invention elucidated the interaction between host-side factors and HIV particles, and provided a method for screening anti-HIV-1 drug targeting a new host-side factor. Furthermore, the present invention provided a new diagnostic method of AIDS based on the interaction. | 2010-02-11 |
20100034745 | Method for Reducing Levels of Disease Associated Proteins - The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid β peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, α-synclein, prion protein, tau and superoxide dismutase 1 (SOD1). | 2010-02-11 |
20100034746 | ANIMAL MODEL, SYSTEM, AND METHOD FOR SCREENING COMPOUNDS FOR ANTITHROMBOTIC AND/OR THROMBOLYTIC ACTIVITY - The present invention relates to a method for evaluating a test compound for antithrombotic activity, thrombolytic activity, or a combination thereof. This method can include providing or employing a donor test animal and a recipient test animal. The donor and recipient test animals can have been pretreated with test compound. The donor test animal can be configured to provide oxygenated blood to the recipient test animal through a thrombus inducing system. This method also includes initiating transport of blood from the donor test animal to the recipient test animal through the thrombus inducing system. The method can include interrupting respiration of the recipient test animal and determining the length of time that the recipient test animal survives. In this method, a survival time longer than a predetermined threshold time indicates that the test compound has antithrombotic activity, thrombolytic activity, or a combination thereof. | 2010-02-11 |
20100034747 | Detection of HIV-1 Infection - This invention provides methods for to the use of the difference in phosphodiester (PDE)/phosphomonoester (PME) ratio in biological fluids, as an analytical criterion to image both the presence and degree of viral infection in-vivo. | 2010-02-11 |
20100034748 | Molecular imaging probes based on loaded reactive nano-scale latex - The present invention relates to a loaded reactive nanoscale latex particle synthesized from mixture of monomers containing water insoluble monomers, at least two ethylenically functionalities monomers, halo-aromatic-polyethyleneglycol-methacrylate, polyethyleneglycolacrylate containing macromonomers, and up to 10 wt % other ethylenic monomers different from above monomers. The reactive halo-aromatic groups on the surface of latex particle are servable as linkers to react with peptides, antibodies, nucleic acids, ligands or other biomolecules. | 2010-02-11 |
20100034749 | Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases - The present invention relates to cationic colloidal preparations and their use for the diagnosis and/or treatment of ocular diseases. | 2010-02-11 |
20100034750 | COMPOSITION AND METHOD FOR DETECTION OF DEMINERALISATION - The invention relates to a composition for the detection of tooth demineralisation. More specifically, the invention concerns a composition comprising a complex capable of producing an optical signal characteristic of the presence of free ions, the pharmaceutical uses of such a composition, and methods and a kit for the detection of active demineralisation at tooth surfaces using such a composition. | 2010-02-11 |
20100034751 | DEHYDRATED GRANULAR COMPOSITION AND BIOMEDICAL APPLICATIONS THEREOF - The invention relates to a granular composition for a biomaterial, that comprises from 0.1 to 5 wt % of at least one polymer derived from cellulose, 75 to 99.9 wt % of a mineral phase containing hydroxyapatite and/or β tricalcic phosphate, and 0 to 10 wt % of water, preferably 0 to 7 wt % of water, more preferably 0 to 5 wt % of water, and even more preferably approximately 5 wt % of water. | 2010-02-11 |
20100034752 | INHALANT FORMULATIONS COMPRISING A BISPHOSPHONATE AND A PYRAZOLONE DERIVATIVE AND METHODS FOR USING THE SAME - The present invention provides for methods of administering by a pulmonary route a bisphosphonate active agent in combination with a pyrazolone derivative to a subject. Also provided are pharmaceutical compositions for use in practicing methods according to embodiments of the invention. The methods and compositions according to embodiments of the invention find use in a variety of different applications, including but not limited to, the treatment of bone absorption disease conditions. | 2010-02-11 |
20100034753 | EDIBLE FOAM PRODUCT FOR THE TREATMENT OR PREVENTION OF OBESITY - The present invention relates to an edible foam product that can advantageously be used in the treatment or prevention of obesity. More particularly, the present invention provides an edible foam product of pourable or spoonable consistency having an overrun of at least 100%, said foam product containing at least 60 wt. % of water, from 1 to 7 wt. % of protein and from 1 to 20 wt. % of carbohydrates, and further being characterised by a high in-mouth stability as evidenced by a reduction in overrun of less than 35% under in-mouth shear conditions and a high gastric stability as evidenced by a t½>30 minutes, t 1/2 representing the time needed to achieve a reduction in overrun of 50% under gastric conditions. Another aspect of the invention relates to the use of an edible foam product in the treatment or prevention of overweight or obesity, said edible foam product having a pourable or spoonable consistency, an overrun of at least 100% and a high gastric stability as evidenced by t 1/2 >30 minutes. Yet another aspect of the invention concerns a pressurised container holding an edible liquid composition and a propellant, which liquid composition can be released from the container by activating a valve to produce an edible foam product having a pourable or spoonable consistency, an overrun of at least 100% and a high gastric stability as evidenced by t 1/2 >30 minutes. | 2010-02-11 |
20100034754 | METHOD FOR MAKING INSECT REPELLENT COMPOSITION - Dihydronepetalactone, a minor natural constituent of the essential oil of catmints ( | 2010-02-11 |
20100034755 | Oral Care Compositions - In accordance with this invention, there is provided an oral care composition comprising a multimodal blend of copolymers of maleic acid or maleic anhydride and an alkyl vinyl ether and a non-cationic antibacterial agent. The compositions feature improved retention of the antibacterial agent on teeth. | 2010-02-11 |
20100034756 | GRINDING METHOD FOR THE MANIPULATION OR PRESERVATION OF CALCIUM PHOSPHATE HYBRID PROPERTIES - A solid state method of encouraging the physical interfacing of an organic component to a substantially crystalline inorganic component, including adding predetermined amounts of a substantially crystalline inorganic precursor and a predetermined amount of an organic precursor to yield an admixture, maintaining the admixture in a substantially liquid-free environment, and impacting the precursors together with sufficient energy to fuse the precursors into hybrid compounds. The so-formed hybrid compounds substantially retain the long range crystalline order characteristics of the substantially crystalline inorganic precursor. | 2010-02-11 |
20100034757 | EXTRACT POWDER OF INDIGO PLANT, AND ITS PREPARATION AND USES - The present invention has objects to provide an extract powder of indigo plant, which has a relatively low hygroscopicity, satisfactory fluidability, and improved storage stability; a process thereof; and a composition incorporated with the extract powder. The objects are solved by a process for producing an extract powder of indigo plant, which comprises incorporating a partial starch hydrolyzate with a dextrose equivalent of 10.2 or lower into one part by weight, on a dry solid basis, of an indigo plant extract contained in a liquid extract of indigo plant in an amount of not lower than 0.25 part by weight but not higher than 5 parts by weight, on a dry solid basis, and drying the resulting mixture; an extract powder of indigo plant prepared thereby; and a composition incorporated with the extract powder. | 2010-02-11 |
20100034758 | Peptides Modified with Triterpenoids and Small Organic Molecules: Synthesis and use in Cosmeceuticals - The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin. With added peptides which boost the collagen and other matrix protein, Triterpenoid peptides provide a complete protection against pre mature ageing and functions as a best anti ageing ingredient. | 2010-02-11 |
20100034759 | TANNING AID AND KIT FOR USE IN TANNING OF A HUMAN BODY SURFACE - A tanning aid and a kit for use in tanning of a human body surface. The tanning aid comprises a tissue paper and a tanning composition. The tanning composition comprises an effective amount of at least one of a tanning lotion, a tanning oil and a bronzing agent. The tanning composition is impregnated in the tissue paper. A human body surface is wiped with the tissue paper impregnated with the tanning composition for applying the tanning composition to the human body surface. | 2010-02-11 |
20100034760 | Method of Increasing the Tanning Effect of Self-tanning Substances - The invention relates to a method for enhancing the tanning action of at least one self-tanner substance by reducing or eliminating the presence of oxygen. | 2010-02-11 |
20100034761 | PERSONAL CARE AND COSMETICS COMPOSITIONS COMPRISING BIOLOGICALLY-BASED MONO AND DI ESTERS - Personal care compositions comprising esters of 1,3-propanediol and acceptable carriers are provided. The esters can have at least 3% biobased carbon, and the compositions can further comprise 1,3-propanediol that is biologically-derived. Also provided are processes for producing personal care compositions comprising esters of 1,3-propanediol and acceptable carriers. The processes comprise providing biologically produced 1,3-propanediol, contacting the 1,3-propanediol with organic acids, which produces the esters, recovering the esters, and incorporating the esters into personal care formulations. Also provided are processes of making a personal care composition comprising providing an ester of 1,3 propanediol and mixing the ester with an acceptable carrier to form a personal care composition. | 2010-02-11 |
20100034762 | Novel enrichment methods for gallic acid esters including 1-O-galloy1-bata-D-glucose and mucic acid gallates medicaments, therapeutic applications and methods of treatment thereof - Improved methods to prepare aqueous extracts of gallic acid esters including 1-O-galloyl-β- | 2010-02-11 |
20100034763 | Skin Lightening Composition Comprising CO2 Extracts - Skin lightening additives and skin lightening compositions with carbon dioxide obtained plant extracts are described. The compositions are suitable for topical application and may comprise CO | 2010-02-11 |
20100034764 | Method for Preparing a Lipophilic Vine Extract - The present invention relates to a method for preparing a lipophilic extract from lignified portions of vine, such as shoots, stock and roots, characterized in that said method comprises a step for extraction from said lignified portions with an apolar solvent; to an extract obtained by such a method; to the use of such an extract as an excipient in a cosmetic composition; and to a cosmetic composition comprising such an extract. | 2010-02-11 |
20100034765 | USE OF POLYSILOXANES WITH QUATERNARY AMMONIUM GROUPS FOR PROTECTING ANIMAL OR HUMAN HAIR AGAINST HEAT DAMAGE - The invention relates to the use of polysiloxanes containing at least one quaternary ammonium group for protecting animal or human hair against heat damage. | 2010-02-11 |
20100034766 | Malodor Counteracting Compositions - A malodor counteracting composition comprising at least one compound of formula (A) | 2010-02-11 |
20100034767 | COMPOSITION FOR MAKING UP THE LIPS - A cosmetic composition in the form of a water-in-oil emulsion includes a fatty phase and an aqueous phase, the fatty phase of which includes at least one hydrocarbon oil, at least one first copolymer of ethylene and of propylene and at least one second copolymer of styrene and of at least one olefin other than styrene. A cosmetic method for caring for or making up skin or the lips, and the topical application to the lips of this composition are also disclosed. | 2010-02-11 |
20100034768 | COMPOSITION AND METHOD FOR TREATMENT OF INSECT BITES - A composition for treating wounds of the skin, such as those caused by the bites of small insects or jellyfish, includes a wax or resin, an emulsifier, and ammonium hydroxide. The composition is applied to the skin in a thin layer, and when it dries, it forms a thin, protective film over the wound. Application of the composition has been found to provide temporary and immediate relief of pain and/or itching. The protective film shields the wound, and therefore aids in healing. The composition can be made of any of a variety of waxes or resins, and the emulsion can be formed with long-chain alcohol or fatty acid soaps, such as oleic acid or triethanolamine. | 2010-02-11 |
20100034769 | COMPOSITIONS FOR TISSUE AUGMENTATION - Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty). | 2010-02-11 |
20100034770 | ANTIMICROBIAL SURFACES - The present invention relates to compositions having a light activated antimicrobial material connected to an environmental surface, such as fabric, through a linking moiety and a mediator polymer. Also taught herein are surfaces to which the compositions of this invention are attached to impart antimicrobial activity to those surfaces. The present invention facilitates or makes possible the attachment of certain light activated antimicrobial material such as Rose Bengal dye to a surface to achieve antimicrobial activity. | 2010-02-11 |
20100034771 | Combination Of Cytokine And Cytokine Receptor For Altering Immune System Functioning - The invention provides a pharmaceutical composition including a cytokine and a peptide comprising at least a portion of a chemokine receptor or a c_protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma. | 2010-02-11 |
20100034772 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention relates to the technical field of immunology and the treatment of diseases mediated and/or indicated by the presence of a ligand of NK receptor NKG2D, such as major histocompatibility complex class I chain related (MIC) A and B molecules on the cell surface of diseased tissue or cells. In particular, the present invention makes use of the surprising finding that the stress-inducible endogenous danger signals HSP70 and MICA/B synergistically activate NK cells against tumors. Methods and compositions for the prevention and treatment of infectious diseases, primary and in particular metastatic neoplastic diseases, including, but not limited to human sarcomas, carcinomas and melanomas are provided. | 2010-02-11 |
20100034773 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 2010-02-11 |
20100034774 | Serotype of adenovirus and uses thereof - Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. | 2010-02-11 |
20100034775 | RECOMBINANT ADENOVIRUS COMPRISING RECOMBINANT khp53 GENE AND THE PREPARATION METHOD AND USES THEREOF - A recombinant adenovirus vector comprises eukaryotic cell promoter, operator, Kozak sequence, exogenous gene and PolyA signal sequence from 5′ to 3′ in the adenovirus vector backbone. Optionally, introns are inserted between the operator and Kozak sequence, and the exogenous gene is p53 gene. A recombinant adenovirus obtained by co-transfection of the adenovirus vector and adenovirus backbone is also included in the invention. Also disclosed are the preparation methods and uses of the recombinant adenovirus vector and the recombinant adenovirus, respectively. The present invention further discloses a pharmaceutical composition for treating cancers, which comprises the recombinant adenovirus. | 2010-02-11 |
20100034776 | REPLICATION-COMPETENT ANTI-CANCER VECTORS - Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed. | 2010-02-11 |
20100034777 | Method for Regulating Protein Function in Cells In Vivo Using Synthetic Small Molecules - Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described. | 2010-02-11 |
20100034778 | STEM CELLS - The present invention relates, in general, to stem cells and, in particular, to a method of expanding human stem cells using a retinoic acid receptor modulator. | 2010-02-11 |
20100034779 | COMPOSITIONS AND METHODS FOR PRODUCING PLURIPOTENT CELLS FROM ADULT TESTIS - The present application describes a method of producing embryonic stem cell (ESC)-like cells derived from adult mammalian testis. Furthermore, the application describes to a method of producing embryoid bodies from ESC-like cells as well as a method of producing a tissue and/or a differentiated cell from the ESC-like cell or the embryoid body. In addition, an ESC-like cell, an embryoid body and/or differentiated cell and/or tissue obtainable by said methods and pharmaceutical preparations containing the same are provided. Finally, the application describes to the use of these products for medical treatments and the preparation of pharmaceutical compositions for medical treatments. | 2010-02-11 |
20100034780 | TUMOR ANTIGEN PEPTIDE DERIVED FROM AMACR - The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like. | 2010-02-11 |
20100034781 | Oxysterol Compounds and the Hedgehog Pathway - This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention. | 2010-02-11 |
20100034782 | Methods of Using Anti-Thymocyte Globulin and Related Agents - Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases. | 2010-02-11 |
20100034783 | Medical kit and using method thereof - An aseptic/sterile medical kits are comprising a cartilage regeneration kit, a bone regeneration kit or an umbilical cord blood storage kit in a configuration that each process performs according to functionally-specialized kit sets for each step, via division of overall processes into corresponding steps for isolation, culture, collection and storage of cells, and implantation of desired cells into target sites of the body. The cartilage is regenerated by cartilage tissue collection; chondrocyte isolation; chondrocyte medium change and subculture; preparation of chondrocyte therapy product; media for isolation/culture/preparation/cryopreservation of cells; and media for isolation/culture/cryopreservation of cells, using the cartilage regeneration kit. The bone is regenerated by bone marrow collection; osteoblast isolation; osteoblast medium change and subculture; and preparation of osteoblast therapy product, using the bone regeneration kit. Additionally, the umbilical cord blood is stored by umbilical cord blood collection; hematopoietic stem cell isolation; and cryopreservation of hematopoietic stem cells, using the umbilical cord blood storage kit. | 2010-02-11 |
20100034784 | USE OF FUSED NICOTINAMIDES TO PROMOTE NEUROGENESIS - The present invention provides a group of compounds found to increase the number of neurons derived from stem cells for use as a therapeutic agent in neurological conditions or diseases. In one embodiment of the present invention, the compounds are used to detect the mechanism by which the number of neurons is increased. | 2010-02-11 |
20100034785 | Differentiation of Pluripotent Cells into Primary Germ Layer Progenitors - This invention relates to the culture of pluripotent cells in a fully humanised chemically defined medium. Cells may be cultured over a prolonged period of time without losing their pluripotent status or may be controllably induced to differentiate into progenitor cells of the three primary germ layers by the addition of differentiation factors, for example differentiation factors which modulate one or more of the Activin/Nodal, FGF, Wnt or BMP signalling pathways. | 2010-02-11 |
20100034786 | Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells - The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PBK alpha or PBK delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PBK inhibitors, PBK inhibitors for particular uses, and kits. | 2010-02-11 |
20100034787 | COMPOSITION AND METHODS FOR PROMOTING HAIR GROWTH - The present disclosure provides compositions and methods for promoting the growth of hair for cosmetic purposes as well as for treating disorders of hair growth. The compositions are conditioned media obtained from a three dimensional tissue that produces a combination of cellular factors effective to induce, promote, or enhance hair growth. | 2010-02-11 |
20100034788 | Method for diagnosing and treating bone-related diseases - The present invention relates to the field of molecular biology and medicine. The present invention relates to the use of polynucleotides encoding a mammalian PLEKHM1 polypeptide and the polypeptides encoded by these polynucleotides for regulating bone homeostasis and for diagnostic and/or therapeutic applications. The present invention further relates to vectors, host cells, antibodies, diagnostic and therapeutic methods for detecting and treating diseases, in particular bone-related diseases. | 2010-02-11 |
20100034789 | Novel carbosilane dendrimers, preparation method thereof and use of same - Novel carbosilane dendrimers, their preparation and their uses. The dendrimers of the invention have secondary, tertiary and quaternary amino groups at their branch ends. Their possible uses include vehicles for carrying anionic-charged molecules in the blood, such as nucleic acids, among them ODN and RNAi, and other anionic drugs with which they have the capacity of interacting, protecting them from interaction with plasma protein and/or increasing their penetration rate in target cells. In the cases where the bond is long-lasting, the dendrimers of the invention can be used to fix anionic molecules to surfaces. Their uses also include their administration as active ingredients to prevent or treat diseases caused by micro-organisms with whose structure and/or life cycle they interfere. | 2010-02-11 |
20100034790 | Use of materials for treatment of central nervous system lesions - Disclosed are methods and materials for treatment of central nervous system lesions. Preferred methods and materials comprise neuronal precursor cells and/or marrow adherent stem cell-derived neuronal cells. | 2010-02-11 |
20100034791 | Engineered Lung Tissue Construction for High Throughput Toxicity Screening and Drug Discovery - The present invention relates to compositions comprising fetal pulmonary cells and biocompatible materials. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery. | 2010-02-11 |
20100034792 | COMBINATIONS OF BIOLOGICAL CONTROL AGENTS WITH A NEMATICIDAL SEED COATING - This invention provides combinations of at least one biological control agent and at least one nematicide to enhance plant protection against pests and pathogens. | 2010-02-11 |
20100034793 | METHOD OF USING STROMA CELLS FROM CORD BLOOD TO EXPAND AND ENGRAFT NUCLEATED CELLS FROM CORD BLOOD - The invention features a method for expanding and engrafting nucleated cells, e.g., progenitor cells, such as hematopoietic cells, obtained from cord blood by co-culturing the nucleated cells with adherent stroma cells, e.g., mesenchymal stem/progenitor cells, also obtained from cord blood. | 2010-02-11 |
20100034794 | ENDOTHELIAL PROGENITOR CELL COMPOSITIONS AND NEOVASCULARIZATION - Methods and compositions are provided for inducing neovascularization in injured tissues with endothelial progenitor cells (EPCs). Mixtures of purified CD34+ endothelial progenitors and purified CD14+ monocytes, or products of an in vitro co-culture of purified CD34+ endothelial progenitor cells and purified CD14+ monocytes provide neovascularization after administration to a subject having a tissue injury, such as an ischemic injury. | 2010-02-11 |
20100034795 | USE OF L-CARNITINE OR ALKANYL L-CARNITINE FOR THE PREPARATION OF A DIETARY SUPPLEMENT OR MEDICAMENT FOR THE TREATMENT OF CORNEAL DISEASE - Use of L-carnitine and/or one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of a dietary supplement or medicament for the treatment of corneal diseases is disclosed. | 2010-02-11 |
20100034796 | Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction - Described are a method and a composition for preventing and/or treating a disease related to mitochondrial dysfunction by inhibiting the fatty acid oxidation of one or more cells of an organism. Particularly, the fatty acid oxidation is inhibited by inhibiting the expression and/or activity of the enzyme Carnitin-Palmitoyl-Transferase- | 2010-02-11 |
20100034797 | Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the | 2010-02-11 |
20100034798 | COMPOSITION AND METHOD OF USE FOR INTESTINAL HEALTH - Therapeutic compositions can include ingredients to be useful in methods for improving or maintaining proper intestinal health. The therapeutic compositions can be used for maintaining a healthy intestinal tract by providing essential nutrients for intestinal function. Also, the therapeutic compositions can improve intestinal health by providing functional ingredients that can be useful for returning the intestinal tract to a healthy condition for optimal performance. The therapeutic compositions can be beneficial for small and large intestines, and other aspects of the GI tract as well as for the general heath of an individual. | 2010-02-11 |
20100034799 | ANTI-COCAINE COMPOSITIONS AND TREATMENT - Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides. | 2010-02-11 |
20100034800 | COMPOSITIONS FOR DETECTING CELL DEATH AND METHODS OF USE THEREOF - The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis. | 2010-02-11 |
20100034801 | Non-Polymeric Compositions for Controlled Drug Delivery - The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a bioactive substance in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic non-polymeric material; (c) an ionic complex that is formed between an amphiphilic molecule and a bioactive substance having a net charge at neutral pH in water. The present invention also provides a method of manufacturing and use of the composition thereof. | 2010-02-11 |
20100034802 | TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. | 2010-02-11 |
20100034803 | ACTIVATING AGENT OF STEM CELLS AND/OR PROGENITOR CELLS - The present invention provides an activating agent of stem cells and/or progenitor cells comprising a thrombin-like enzyme which can be used in regenerative medicine, and particularly in regenerative medicine utilizing self-regeneration, acting promptly and moderately depending on the state of advancement and the degree of injured organs and/or tissues to which regenerative medicine is applied, with few or no side effects. The present invention also provides a method for activating stem cells and/or progenitor cells in an animal comprising the step of administering to the animal an effective amount of a thrombin-like enzyme and use of the thrombin-like enzyme for activating stem cells and/or progenitor cells. | 2010-02-11 |
20100034804 | MUTANTS OF STREPTOKINASE AND THEIR COVALENTLY MODIFIED FORMS - The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants. | 2010-02-11 |
20100034805 | KALLIKREIN-INHIBITOR THERAPIES - Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. | 2010-02-11 |
20100034806 | Methods and Compositons for the Treatment of Marfan Syndrome and Associated Disorders - The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. | 2010-02-11 |
20100034807 | METHODS AND COMPOSITIONS FOR DISCOVERY OF TARGET-SPECIFIC ANTIBODIES USING ANTIBODY REPERTOIRE ARRAY (ARA) - The invention provides antibody arrays specific for target antigens. Methods for discovery and compositions comprising native human antibodies, arrays comprising such antibodies, immortalized B cells expressing such antibodies and non-immortalized B cell libraries comprising B cells expressing such antibodies are provided. The invention provides a method for screening monoclonal antibodies for functional effects on cell surface molecules such as receptors using antibody repertoire arrays specific for target cell surface molecules. Functional antibodies directed to a target and therapeutics derived from such antibodies are also provided. High throughput and parallel screening for potentially therapeutic antibodies are provided. Antibodies directed to functional epitope clusters corresponding to a target and vaccines and therapeutics derived from such antibodies are also provided. | 2010-02-11 |
20100034808 | COMPOSITIONS AND METHODS FOR PRESERVING CELLS OF THE EYE - The invention provides a method of preserving ocular cells in a patient having or at risk of developing glaucoma. In particular, microglial cell activation can be decreased, oligodendrocyte loss can be reduced, and/or the viability of retinal ganglion cells can be preserved by administering a selective TNFR2 antagonist to an individual having or at risk of developing glaucoma. | 2010-02-11 |